Paris, January 26, 2022 – 6:30 p.m. CET – Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO), a company specializing in the early and precise detection of cancerous diseases with a unique fully automated solution for medical analysis laboratories, announces today today the initiation of coverage of the “commissioned research” type of its title by Sphene Capital, with a study entitled “Restart of a technology leader in laboratory automation”.
The Sphene Capital study presents a target valuation of €7.70 per share with an investment recommendation to “buy”.